A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101

Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Back to Results

A Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OP-101 (dendrimer n-acetyl-cysteine) in Patients with Severe COVID-19

Objective

Clinical Trial Details>>

Principal Investigator(s)

John Aita, MD

Clinical Trial Categories

COVID-19
Adult
Infectious Disease

Sponsor(s)

Ashvattha Therapeutics, Inc.

Contact

Avera Research Institute at 605-504-3154
or ARI@Avera.org

Location

Avera Research Institute — Sioux Falls
6001 S Sharon Ave
Sioux Falls, SD 57108
Main: 605-504-3154